StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research note released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.
Acorda Therapeutics Stock Performance
Shares of NASDAQ ACOR opened at $0.40 on Friday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.49 and a current ratio of 1.86. The firm has a market cap of $5.31 million, a price-to-earnings ratio of -0.05 and a beta of 0.45. The business's 50-day simple moving average is $0.44 and its 200-day simple moving average is $0.89. Acorda Therapeutics has a 52 week low of $0.28 and a 52 week high of $4.99.
Get Acorda Therapeutics alerts:Institutional Trading of Acorda Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. bought a new stake in shares of Acorda Therapeutics in the 2nd quarter worth approximately $28,000. Virtu Financial LLC bought a new position in shares of Acorda Therapeutics during the 2nd quarter worth approximately $68,000. Millennium Management LLC lifted its position in shares of Acorda Therapeutics by 661.2% during the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after buying an additional 270,588 shares during the period. Acadian Asset Management LLC lifted its position in shares of Acorda Therapeutics by 22.3% during the 4th quarter. Acadian Asset Management LLC now owns 467,739 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 85,335 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Acorda Therapeutics by 27.4% during the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock worth $420,000 after buying an additional 194,100 shares during the period. Institutional investors and hedge funds own 50.24% of the company's stock.
About Acorda Therapeutics
(Get Rating)Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.